The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
Open accessAbstract
Microglia play a pivotal role in the maintenance of brain homeostasis but lose homeostatic function during neurodegenerative disorders. We identified a specific apolipoprotein E (APOE)-dependent molecular signature in microglia from models of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease (AD) and in microglia surrounding neuritic β-amyloid (Aβ)-plaques in the brains of people with AD. The APOE pathway mediated a switch from a homeostatic to a neurodegenerative microglia phenotype after phagocytosis of apoptotic neurons. TREM2 (triggering receptor expressed on myeloid cells 2) induced APOE signaling, and targeting the TREM2-APOE pathway restored the homeostatic signature of microglia in ALS and AD mouse models and prevented neuronal loss in an acute model of neurodegeneration. APOE-mediated neurodegenerative microglia had lost their tolerogenic function. Our work identifies the TREM2-APOE pathway as a major regulator of microglial functional phenotype in neurodegenerative diseases and serves as a novel target that could aid in the restoration of homeostatic microglia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DAM response is dependent on TREM2 and APOE, two major AD risk genes, in mouse models of AD and metabolic disease (Krasemann et al., 2017; Pimenova et al., 2017a).”
From Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response (2021) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Krasemann et al. found that APOE can bind with the intracellular domain of TREM2 and switch microglia from a homeostatic phenotype to neurodegenerative phenotype in multiple neurodegenerative models including AD, indicating APOE-TREM2 pathway as a proinflammatory signaling.182”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [182]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial accumulation at plaques and plaque-driven morphological and transcriptional responses depend on microglial surface receptor-mediated signalling8,12,13,29, which involves activation of the tyrosine kinase (SYK)9,30 and one of its key downstream targets (PLCγ2)31,32.”
From Lymphoid gene expression supports neuroprotective microglia function (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Addressing this question directly, more recent studies combining single-cell transcriptomics with fate-mapping studies, in both animals and humans, have revealed that some of the macrophage subsets identified during disease are activation states of tissue resident macrophages (35–38).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These pathways highlight how neuronal and glial interactions modulate microglial activity through Apoe, App, Trem2, and Lrp1 [Krasemann et al., 2017; Lin & Holtzman 2024; Shinohara et al., 2017].”
From Cell signaling pathways discovery from multi-modal data (2025) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most notably, emerging evidence from both AD patients and neurodegenerative mouse models has identified key roles for TREM2, CD33, and CD22 in disease progression (Bemiller et al., 2017; Krasemann et al., 2017; Malik et al., 2013; Pluvinage et al., 2019; Ulland et al., 2017; Wang et al., 2015).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This pathway regulates the switch from a homeostatic to a neurodegenerative molecular signature by inducing miR155 via apolipoprotein E (APOE) signaling,48”
From Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease (2023) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This supports a protective role for the DAM/MGnD microglial phenotype, with TREM2-dependent functions potentially required initially to prevent seeding of plaques, whilst later enhancing the consolidation of Aβ into compact aggregates to protect neurons from Aβ-induced injury.”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD patients carrying mutations in TREM2 genes display less compact Aβ plaques and fewer plaque-associated microglia but enhanced tau pathology and neuritic plaques [191, 361]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Single-cell RNA sequencing identified gene signatures characteristic of protective and dysfunctional microglial subpopulations in AD9,10.”
From Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, DAM and MGnD are best understood not as inherently beneficial or harmful categories, but as context-dependent responses whose net effect depends on disease stage, brain region, and the balance between phagocytic containment and inflammatory injury.”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Existing categories such as DAM and MGnD have already shown that microglia can enter disease-linked states, but they do not fully explain how protective immune regulation is achieved within the Alzheimer’s brain.”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, the phenotype of microglia we observed in HDLS is similar to that found in an SOD1 ALS mouse model and in multiple sclerosis patients, in which the molecules associated with the homeostatic microglial phenotype (e.g., P2RY12, CSF-1R) are down-regulated and inflammatory markers are up-regulated [24, 57].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CD11c+ microglia are known to increase in chronic inflammatory and neurodegenerative conditions as well as during development [76–83]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our findings in humans were validated in mice with inactivated Plcg2 expression (PLCG2 inact), which reduced expression levels of AD-associated microglial genes [39, 40], including CLEC7A, C3, and PIK3R5, in comparison with expression levels of these genes in WT mice.”
From PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer’s disease (2022) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The existence of DAM in mice and humans has recently been confirmed in tauopathy AD models (26, 27), aging (27, 28), and other neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) (29) and multiple sclerosis (30).”
From Therapeutic Idol reduction ameliorates amyloidosis and improves cognitive function in APP/PS1 mice (2020) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ligation of the Trem2 receptor by ApoE is sufficient to promote phagocytosis in TREM2-expressing microglial (brain-resident macrophage) cells and, in turn, activates Apoe RNA expression,89”
From Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High-confidence Trem2+ monocytes were identified by expression of known TREM2+ monocyte markers (TREM2, APOE, CSF1R81,89), identified by gene-weighted density estimation implemented in the Nebulosa package for R.78”
From Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been demonstrated that this in vivo model induces a well-defined microglial proinflammatory phenotype different to the recently characterized molecular signature of disease-associated microglia (Bodea et al., 2014; Krasemann et al., 2017).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, these aggregated forms play leading roles in driving main pathogenic events in these neurodegenerative diseases with the active involvement of highly activated microglia, more recently referred to as disease-associated microglia (Krasemann et al., 2017) (Keren-Shaul et al., 2017) (Mathys et al., 2017).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We also found that microglial TET2 is upregulated in vivo in two-well defined models of microglia polarization; in a neuroinflammatory mouse model induced by repeated intraperitoneal injections of LPS (Krasemann et al., 2017; Bodea et al., 2014), and in AD, including human patients and transgenic mice (5xFAD).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Twenty one core genes associated with XO4+/XO4− phenotype were identified as altered in several studies of neurodegenerative disease-associated microglia (DAM)13,14,32”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The XO4+-associated gene expression signature identified here partially overlaps with other microglia signatures obtained from aged, APP/PS1, 5xFAD or tau model mice13,14,31–33”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies13,14 identified a novel microglial phenotype near Aβ plaques that was dependent on Trem2 and Apoe in two mouse models of AD.”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that plaque-adjacent microglia in human post mortem AD brains upregulate LPL13 and downregulate P2RY1214”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We demonstrate here, in agreement with previous findings (Keren-Shaul et al., 2017; Krasemann et al., 2017), that ARMs induce Apoe expression up to 27-fold, compared to homeostatic microglia.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dysregulation of the TREM2/ APOE axis has been implicated in heightened neuroinflammation, neuronal injury, and complement-mediated synaptic clearance, representing a critical therapeutic target in AD pathology (68).”
From Molecular and cellular processes disrupted in the early postnatal Down syndrome prefrontal cortex (2026) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with other studies, we observe an upregulation in DAM genes (i.e., Cst7, Apoe, Ctsb, Ctsd, Ctss, and Psen1) and downregulation in homeostatic genes (P2ry12, Tmem119, and Csf1r) in 5xFAD compared to WT mice [48, 57, 58].”
From APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Together with triggering receptor expressed on myeloid cells 2 (TREM2), APOE has also been shown to regulate microglial response to Aβ plaques and neurofibrillary tangles in AD as well as in other neurodegenerative diseases150.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE reduction or depletion attenuates neuroinflammation and alleviates pathological changes in various mouse models of amyloid and tau pathology”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Krasemann et al 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“carriage of the E4 allele is associated with increased neuroinflammation and metabolic disturbances within neurons and glial cells (Krasemann et al., 2017)”
From APOE4 reshapes the lipid droplet proteome and modulates microglial inflammatory responses (2025) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MGnD (p < 0.05 relative to TG-Abi3-Gngt2+/−) [25]”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis revealed 5 discrete microglial clusters, each representing a different microglial state, including previously characterized homeostatic, transitioning, activated plaque-responsive (Act), and interferon (IFN)-responsive microglial subsets 1,3,33 (Figure 7A and 7B).”
From Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer’s disease (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Shared DEGs from both datasets were associated with enhanced IFN signaling, indicating the IFN pathway as an early response in microglia reacting to remote pathological changes 7,34 (Fig 1h,i).”
From Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer’s disease (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the current work, we focus on cholesterol 25-hydroxylase (Ch25h), which is upregulated in DAM only when both Apoe and Trem2 are present (Krasemann et al., 2017; Zhou et al., 2020).”
From Cholesterol 25-hydroxylase mediates neuroinflammation and neurodegeneration in a mouse model of tauopathy (2024) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A two-stage activation of microglial phenotype, switching from a homeostatic state to DAM, has been shown to be Apoe and Trem2 dependent (Krasemann et al., 2017; Deczkowska et al., 2018; Keren-Shaul et al., 2017).”
From Cholesterol 25-hydroxylase mediates neuroinflammation and neurodegeneration in a mouse model of tauopathy (2024) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Single-cell transcriptomic analysis carried out in AD human and AD mouse model brain tissue have identified unique signatures of gene expression in microglia in physical proximity to amyloid plaques and tau aggregates, termed DAM (Keren-Shaul et al., 2017; Krasemann et al., 2017; Zhou et al., 2020).”
From Cholesterol 25-hydroxylase mediates neuroinflammation and neurodegeneration in a mouse model of tauopathy (2024) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cluster 1 is characterized by high expression of mRNA for markers (e.g., Apobec, Apoe, Axl, Cd9, and Lpl) typical of the transcriptomic signature referred to as microglial neurodegenerative (MGnD) or DAM (Fig. 8 D and Table S9) (Deczkowska et al., 2018; Keren-Shaul et al., 2017; Krasemann et al., 2017).”
From Cholesterol 25-hydroxylase mediates neuroinflammation and neurodegeneration in a mouse model of tauopathy (2024) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In aging or neurodegeneration, mouse microglia adopt Apoe and Trem2-dependent disease-associated or neurodegenerative microglia phenotype (DAM, MGnD), upregulating Apoe (Keren-Shaul et al., 2017; Krasemann et al., 2017).”
From Cholesterol and matrisome pathways dysregulated in astrocytes and microglia (2022) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In studies of microglial activation in amyloid models, MHC-II and Spp1 were elevated in an advanced activated state (activated response microglia (ARM)) that corresponded with high levels of Apoe expression (Krasemann et al., 2017; Sala Frigerio et al., 2019).”
From Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of CNS damage resulting from Aβ, tau, SOD-1, or other pathologies, apoE is strongly upregulated in microglia coincident with the DAM or MGnD phenotype (Butovsky et al., 2015; Keren-Shaul et al., 2017; Krasemann et al., 2017; Parhizkar et al., 2019; Shi et al., 2017).”
From Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the central nervous system (CNS), ApoE is primarily secreted by astrocytes under homeostatic conditions with microglia upregulating ApoE secretion under multiple disease conditions [18–20, 93–95].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of AD pathology, such as amyloid-β (Aβ) plaques or tauopathy, microglia strongly upregulate APOE expression (4, 11).”
From Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Second, in case–control frameworks, we demonstrate with our reanalysis of two examples from the literature that, without knowledge of the presence of the exAM signature, it can result in spurious identification of the exAM signature as differentially expressed (Supplementary Note 4)41,42,69,70.”
From Dissection of artifactual and confounding glial signatures by single-cell sequencing of mouse and human brain (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“These opposing states are accompanied by broad changes in gene expression12–17, suggesting that defined transcriptional programs in microglia may govern their neuroprotective or neurotoxic functions.”
From Lymphoid gene expression supports neuroprotective microglia function (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Extensive work has characterized microglial receptor TREM2 as influential in driving microglial acquisition of the DAM transcriptome (Keren-Shaul et al., 2017; Krasemann et al., 2017; Wang et al., 2015).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“Recently, it has been shown that several subsets of microglia with unique molecular and functional phenotypes exist in the healthy, aged, and degenerating brain3–5.”
From Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain (2020) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Support for beneficial outcomes associated with maintenance and/or restoration of homeostatic functions of microglia comes from the numerous studies targeting the members of this pathway, including Trem2,48,50–52 Tyrobp,53,54 and miR155.41,55”
From Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease (2023) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“P2RY12 is considered a homeostatic microglia marker because of its downregulation in neurogenerative and neuroinflammatory models, including amyotrophic lateral sclerosis, AD (Table 5) and MS (Table 6) [174, 179, 191, 214], which have been more extensively investigated than encephalitis (Table 3) and stroke (Table 4).”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“Recent transcriptomic studies have identified a subset of microglia that adopt unique transcriptional and functional signatures, termed ‘disease-associated microglia’ (DAM) [179] or ‘microglial neurodegenerative’ (MGnD) phenotype during neurodegeneration [191]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“in mice with cerebral amyloidosis, genetic ablation of TREM2 abrogated the MGnD phenotype and reduced the microglial response to plaques [191]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“mechanistic studies of the TREM2–APOE pathway showed that microglial phenotypes in neurodegeneration are actively regulated transcriptional programs, not passive responses to tissue damage [16].”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“A neurodegenerative disease-associated microglial signature has also been described, termed MGnD [24].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“The two disorders may lie on a disease spectrum, possibly converging via the TREM2-APOE pathway previously reported to be associated with MGnD [24].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“MGnD represents an induced inflammatory signature mediated by the triggering receptor expressed on myeloid cells 2 (TREM2)-apolipoprotein E (APOE) pathway, which suppresses the M0 signature.”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“For example, Trem2, a known AD risk gene expressed in microglia (Krasemann et al., 2017; Sims et al., 2017), is present in Signatures A and C.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“Recent findings point to microglia heterogeneity in neurodegeneration [36, 38].”
From Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph (2019) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The transcriptional shift microglia undergo in response to Aβ is thought to be at least partially dependent on TREM2 expression, 33 , 39”
From PLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology (2025) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“In recent years, a critical role for transcriptional changes in microglial activation has been highlighted, and unique RNA signatures are used to identify distinct microglial subpopulations [5, 52].”
From The protective PLCγ2-P522R variant mitigates Alzheimer’s disease-associated pathologies by enhancing beneficial microglial functions (2025) · cites this paper as [52]
The cited source says what the claim attributes to it.
In the citing paper
“In the central nervous system, APOE is upregulated in MGnD 4,5 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“We identified that neurodegenerative microglia (MGnD) 4 , also referred to as disease-associated microglia 5 , are regulated by the reciprocal suppression of transforming growth factor-β (TGFβ) and induction of apolipoprotein E (APOE) signaling in different neurodegenerative models, including AD 4 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Additional characterization of microglia by analyzing the acute response to neurodegeneration via intracranial injection of apoptotic neurons 4 showed upregulation of antigen presentation- and IFNγ signaling-related genes in Itgb8 -cKO mice compared to in control mice (Extended Data Fig. 8e-g and Supplementary Table 8).”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Single-cell transcriptional profiling of cGAS gain-of-function mice further reveals that, beyond type I IFNs, cGAS activation alone triggers a core microglial gene expression program that is shared between many neurodegenerative disease states and during ageing38–40,51.”
From cGAS–STING drives ageing-related inflammation and neurodegeneration (2023) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“The potential involvement of TET2 in the recent characterized disease-associated microglia (Keren Shaul et al., 2017; Krasemann et al., 2017) is deduced from analysis of both AD transgenic mice and human AD tissues in which TET2 was highly upregulated specifically in amyloid plaque-associated microglia.”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“our analysis identified 2031 (out of 2810, 72.3%) genes associated with XO4+ microglia that were not reported in previous RNA-sequencing studies of microglia in neurodegeneration13,14,33”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“APOE is involved in the regulation of DAMs and the microglial response to amyloid [57, 64–66].”
From APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology (2025) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“Krasemann et al. showed that the DAM (DAM/MGnD) signature is dependent on the TREM2-APOE pathway [57].”
From APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology (2025) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“We performed snRNA-seq to identify cell type-specific transcriptomic changes, and discovered that E3S/S reduced cGAS-STING-IFN signaling in microglia without affecting disease-associated microglial signatures (DAMs)17 or microglial neurodegenerative phenotype (MGnD)18.”
From The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“We performed snRNA-seq to identify cell type-specific transcriptomic changes, and discovered that E3S/S reduced cGAS-STING-IFN signaling in microglia without affecting disease-associated microglial signatures (DAMs)17 or microglial neurodegenerative phenotype (MGnD)18.”
From The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“its expression is markedly upregulated by reactive microglia in the brains of individuals with AD96,150.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [150]
The cited source says what the claim attributes to it.
In the citing paper
“This upregulation is a key element of a conserved transcriptional signature of reactive microglia that has been found in multiple neurodegenerative diseases150,151.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [150]
The cited source says what the claim attributes to it.
In the citing paper
“microglia-derived apoE was shown to cell-autonomously promote microglial activation towards the neurodegenerative “MGnD/DAM” phenotype (Krasemann et al., 2017).”
From Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms (2021) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“Apoe is one of the most upregulated genes in a subset of microglia with neurodegenerative phenotype in amyloid mouse models”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Krasemann et al 2017
The cited source says what the claim attributes to it.
In the citing paper
“The phenotype of disease-associated microglia (DAM) is dependent on the TREM2-apoE pathway, and deletion of apoE might prevent DAM development”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Krasemann et al 2017
The cited source says what the claim attributes to it.
In the citing paper
“In AD mouse models, there is a subset of microglia exhibiting a neurodegenerative/disease-associated phenotype characterized by upregulation of pro-inflammatory genes”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Krasemann et al 2017
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, microglia can significantly upregulate APOE expression as part of their DAM (Disease Associated Microglia) response to the amyloid plaques (Chen et al, 2020; Keren-Shaul et al, 2017; Krasemann et al, 2017; Sala Frigerio et al, 2019).”
From APOE from astrocytes restores Alzheimer’s Aβ-pathology and DAM-like responses in APOE deficient microglia (2024) · cites this paper as Krasemann et al, 2017
The cited source says what the claim attributes to it.
In the citing paper
“The DAM response is dependent on APOE expression (Krasemann et al, 2017; Sala Frigerio et al, 2019) but it was thought that APOE expression in microglia was essential.”
From APOE from astrocytes restores Alzheimer’s Aβ-pathology and DAM-like responses in APOE deficient microglia (2024) · cites this paper as Krasemann et al, 2017
The cited source says what the claim attributes to it.
In the citing paper
“These genes are also reported to be associated with pathologic signatures in AD, most notably DAM and MGnD [24, 25] and PIG [21]”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, two recent studies have reported a phenotypic change of microglia in neurodegenerative diseases from homeostatic to disease-associated microglia (DAM) [62, 63].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [63]
The cited source says what the claim attributes to it.
In the citing paper
“Apoe is one of the most striking TREM2-dependent damage-associated microglia genes”
From TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge (2020) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“microglial responses in the Apoe–/– phenocopy those of Trem2–/– in specific paradigms, such as phagocytosis of apoptotic neurons”
From TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge (2020) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“Previous in vitro and in vivo studies suggested a role for apoE in mediating TREM2-dependent phagocytosis of apoptotic neurons (Atagi et al., 2015; Krasemann et al., 2017).”
From Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“However, in the setting of brain injury or neurodegeneration, APOE expression is strongly upregulated in microglia (Krasemann et al., 2017).”
From Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“Selective removal of APOE from microglia attenuated facial motor neuron death after axotomy, indicating that microglial apoE expression plays a key role in promoting the DAM/MGnD transcriptional state (Krasemann et al., 2017).”
From Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“Selective removal of APOE from microglia attenuated facial motor neuron death after axotomy, indicating that microglial apoE expression plays a key role in promoting the DAM/MGnD transcriptional state (Krasemann et al., 2017).”
From Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021) · cites this paper as Krasemann et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“many of the activated “disease-associated microglia” (DAM) signatures observed in 5xFAD microglia (Keren-Shaul, Spinrad et al. 2017) are also observed in other models of neurodegeneration (neurodegenerative microglia, MGnD) including amyotrophic lateral sclerosis (ALS), or multiple sclerosis (MS) (Krasemann, Madore et al. 2017).”
From SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain (2026) · cites this paper as Krasemann, Madore et al. 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the context of neurodegeneration, microglia strongly upregulate ApoE expression (4, 11).”
From Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform (2026) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cathepsin B signal appears punctate when localized to the lysosomes, whereas the signal becomes diffuse (and perhaps below the limit of detection by immunostaining) when localized to the cytosol upon LMP44–46.”
From INPP5D/SHIP1 regulates endo-lysosomal function and cargo-selective phagocytosis in human microglia (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Based on the previous literature42,43,46, we reasoned that cathepsin B leaking from the destabilized lysosomes may mediate the NLRP3 inflammasome activation upon SHIP1 inhibition11.”
From INPP5D/SHIP1 regulates endo-lysosomal function and cargo-selective phagocytosis in human microglia (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The intracellular signaling pathway downstream TREM2 is complex and involves many molecules in addition to PLCG2, including Syk and PI3K. 32 , 33 , 35 , 43 , 58 , 59”
From PLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“TREM2 is one of the key receptors modulating PLCγ2 activity [12, 36, 37].”
From Protective PLCG2 variants associate with a delayed onset of Alzheimer’s disease among heterozygous APOE ε4 carriers (2026) · cites this paper as [37]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SHIP1 protein expression was identified in plaque-associated microglia of 5xFAD mice, with phagocytic microglia showing a reduction of Inpp5d expression compared to non-phagocytic microglia [168, 169].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [169]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Validation data for all commercial antibodies are available on the manufacturer's website including previously published papers as below:”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Based on publicly available data in this model (Krasemann et al., 2017), we focused on the expression of the two highest induced genes upon repeated systemic LPS injections, Ptgs2 and Cybb (also known as Cox2 and Nox-2 respectively), where both genes are considered as proinflammatory mediators (Alhadidi and Shah, 2018; Benusa et al., 2017).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is noteworthy to mention that in different single cell RNAseq of microglia in different AD models, the expression of TET2 was found not to be upregulated (Krasemann et al., 2017) (Keren-Shaul et al., 2017) (Mathys et al., 2017).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Krasemann et al., 2017
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is interesting to note that Hif1a is not a signature gene described by Krasemann et al.14”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In these studies, CH25H has been identified as one of the upregulated genes featured in the DAM subcluster, which is characterized by expression of typical microglial markers, Iba1, Cst3, and Hexb, and upregulation of genes involved in phagocytosis and lipid metabolism, including Apoe, Ctsd, Lpl, Tyrobp, and Trem2 (reviewed by Deczkowska, et al. 2018) [64].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [63]
Experimental — accuracy not yet measuredIn the citing paper
“These controversial outcomes highlight a complex dual role of microglia also observed in other brain diseases [54,55,56] and might be attributed to the fact that the total removal of microglia might be harmful, whereas targeting specific microglia activation states later in disease might prolong survival time.”
From Loss of Homeostatic Microglia Signature in Prion Diseases (2022) · cites this paper as [55]
In the citing paper
“Fittingly, we found that the loss of the homeostatic signature is especially severe in prion diseases compared to other neurodegenerative conditions [47,55].”
From Loss of Homeostatic Microglia Signature in Prion Diseases (2022) · cites this paper as [55]
In the citing paper
“The loss of homeostatic microglial proteins is visible in immunofluorescence double-staining of IBA1 and TMEM119 in terminally sick mice and mock-infected healthy control brains, and shows the reciprocal regulation of both proteins in prion disease (Figure 5A) [55,73,88,89,90,91].”
From Loss of Homeostatic Microglia Signature in Prion Diseases (2022) · cites this paper as [55]
In the citing paper
“We and others have identified a disease-specific microglia signature that is commonly dysregulated in brain diseases including AD [55,101].”
From Loss of Homeostatic Microglia Signature in Prion Diseases (2022) · cites this paper as [55]
In the citing paper
“Such activated microglia, which have been referred to as disease-associated microglia (DAM), has a transcriptional signature quite distinct from that of homeostatic microglia that markedly declines in mouse models of AD10,11,12.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [11]
In the citing paper
“These results were highly concordant between the 7-month- and 15-month-old datasets (Fig. 2d) and with previously published single cell RNA-seq data of sorted microglia10,11,12.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [11]
In the citing paper
“Altogether, these data suggest that the signature of human microglia in AD is quite distinct from that of DAM in the 5XFAD model10,11: it is reminiscent of the reactive phenotype observed in PNI and may be in part instructed by IRF8.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [11]
In the citing paper
“In mice accumulating Aβ, microglia swap their “homeostatic” signature with a DAM signature that is partially Trem2-dependent10,11.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [11]
In the citing paper
“Several genetically distinct subtypes of microglia have been discovered as they respond to signals or challenges in the brain microenvironment, namely homeostatic microglia and “disease-associated microglia” (DAM) or “microglial neurodegenerative phenotype” (MGnD).99,100”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [100]
In the citing paper
“Studies using an AD mouse model along with postmortem analyses of human AD brain tissue indicate that activation of the TREM2‐APOE pathway triggers transition in microglia from a homeostatic phenotype to a disease‐associated microglia (DAM) phenotype characterized by an increased inflammatory response. 123”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [123]
In the citing paper
“recent transcriptomic studies of microglia in normal and Aβ-mice identified subpopulations defined as disease-associated microglia (DAM)8,24.”
From Microglia in neurodegeneration (2018) · cites this paper as [24]
In the citing paper
“Physiological housekeeping functions include synaptic remodeling (a function critical for CNS development, homeostasis, and neurodegeneration20–22), migration to sites of neuronal death to phagocytose dead or dying cells23,24 or debris, and maintaining myelin homeostasis25.”
From Microglia in neurodegeneration (2018) · cites this paper as [24]
In the citing paper
“the microglial response to amyloid plaques and/or tau pathology is increasingly thought to cause or contribute heavily to disease-related neurodegeneration [10], [11], [12], [13].”
From Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain (2020) · cites this paper as [10]
In the citing paper
“Most microglia were primarily separated into three cluster groups characterised by different sets of transcription factors: clusters expressing homoeostatic genes (Clusters 0, 1 and 3), inflammatory cytokines (Clusters 2, 4, 5 and 7), or DAM-related genes (Clusters 6 and 8)5,7 (Fig. 3d, e, Supplementary Fig. 5a–f).”
From Cellular senescence in white matter microglia is induced during ageing in mice and exacerbates the neuroinflammatory phenotype (2023) · cites this paper as [5]
In the citing paper
“These observations suggest that meningeal lymphatic ablation leads to a loss of homeostatic microglia, and acquisition of the DAM signature (and/or the neurodegenerative microglial signature)21,22,26, all of which is counteracted by passive immunotherapy.”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [22]
In the citing paper
“apoE signaling in microglia following phagocytosis of apoptotic neurons or in response to Aβ accumulation leads to a transcriptional switch from promoting homeostasis to promoting inflammation and neurodegeneration [150, 151].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [151]
In the citing paper
“Thus, microglia surrounding plaques are a major source of plaque-associated ApoE, supporting recent findings30,31.”
From Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model (2019) · cites this paper as [31]
In the citing paper
“sialoadhesin (SIGLEC1; also known as CD169) is a marker for mature dendritic cells and macrophages in both mice and humans48 and has been proposed as a marker for invading monocyte-derived macrophages in the CNS as it is not expressed in microglia in health or disease49–52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“this method of distinguishing between cell types relies on relative surface marker expression as assessed by flow cytometry, which can have some limitations. For example, CD45 surface expression is known to be upregulated on microglia associated with amyloid-β (Aβ) plaques in the APP/PS1 mouse model of Alzheimer disease (AD)52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“the absence of TGFβ1, a factor known to be required for the in vitro development of the molecular signature characteristic of adult microglia, in the CNS results in a paralytic neurologic disease in mice25.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“The upregulated genes in Aβ-plaque-associated microglia, also known as disease-associated microglia (‘DAM microglia’), included Axl, Apoe, Clec7a, Itgax, Lgals3 and Cst7”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Although it is clear that the DAM microglia identified in these studies are associated with Aβ plaques, it is not clear whether they have a protective or disease-inducing function (FIG. 2b).”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Transcriptomic analysis of microglia in an AD mouse model and in human AD has revealed a proinflammatory signature present in Aβ-plaque-associated microglia52,111,139,140 (FIG. 2a).”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, microglia have a transcriptional phenotype that is similar to that observed in ALS and AD models (see below)52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“This phenotype was not observed in microglia in non-plaque areas, suggesting that the neuroinflammation associated with AD predominantly occurs in plaque-associated microglia.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Moreover, suppression of microglial Cx3cr1 expression is associated with disease progression in EAE52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“ApoE also suppresses the expression of major transcription factors of homeostatic microglia52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“At the same time, there was an increase in the expression of genes encoding transcription factors such as class E basic helix-loop-helix protein 40 (Bhlhe40), transcription factor EC (Tfec), protein C-ets-2 (Ets2) and cAMP-dependent transcription factor ATF3 (Atf3).”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Phagocytosis of apoptotic neurons that were injected into the brain of naive mice suppressed the microglial homeostatic signature and resulted in a transcriptional profile that mimicked the molecular signature of MGnD microglia.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“In disease, several core homeostatic disease genes were suppressed, including those encoding the transcriptional regulators Mef2a, Mafb, Sall1 and early growth response protein 1 (Egr1).”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Across disease models, the induction of genes related to ApoE signalling and the suppression of TGFβ signalling in microglia were associated with neurodegeneration, resulting in a phenotype that was termed ‘MGnD’ (microglia neurodegenerative phenotype).”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“This microglial phenotype switch was shown to be regulated by activation of TREM2-ApoE signalling via phosphatidylserine exposed on the apoptotic neurons52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Although it is not entirely clear how TREM2 regulates microglial signature phenotypes, TREM2 is known to recognize phosphatidylserine on the surface of apoptotic or damaged cells and to initiate ApoE signalling52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Moreover, genetic ablation of Apoe in MGnD microglia restored their homeostatic properties in a cell-autonomous fashion.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Genetic targeting of Trem2 suppressed the ApoE pathway and restored homeostatic microglia in both AD and SOD1 mice52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Consistent with this, in MGnD microglia from Apoe−/− mice, miR-155 expression was suppressed52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Microglial expression of Axl is upregulated and Mer is downregulated in microglia exhibiting the MGnD phenotype52.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [52]
In the citing paper
“Trem2, a myeloid protein involved in microglial survival and proliferation, regulates a checkpoint necessary for DAM and deletion of Trem2 prevents microglial accumulation around Aβ plaques and leads to additional neuritic damage [6, 14–17].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [16]
In the citing paper
“Trem2, a myeloid protein involved in microglial survival and proliferation, regulates a checkpoint necessary for DAM and deletion of Trem2 prevents microglial accumulation around Aβ plaques and leads to additional neuritic damage [6, 14–17].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [16]
In the citing paper
“In the anti-inflammatory/phagocytic DAM module, Apoe was identified as a hub gene strongly associated with AD risk. This agrees with other lines of evidence confirming the role of Apoe in regulating DAM responses and Aβ-clearance in AD [16, 21].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [16]
In the citing paper
“The top enrichment term in this group is “Microglia genes upregulated in neurodegenerative diseases” (p = 2.79E-09; Krasemann et al., 2017).”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Krasemann et al., 2017
In the citing paper
“Since deletion of Trem2 in mice blocks the proper transcriptional activation of microglia in neurodegenerative diseases (Keren-Shaul et al., 2017; Krasemann et al., 2017; Wang et al., 2015), it is difficult to predict a priori whether TREM2 gene dosage increase could broadly or subtly alter the microglial transcriptome response, and what impact it would exert on the disease process.”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Krasemann et al., 2017
In the citing paper
“Prior studies (e.g. Keren-Shaul et al., 2017; Krasemann et al., 2017) and our current one (Figure S1A–S1B) showed elevated Trem2 expression occurs at relatively late disease stages.”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Krasemann et al., 2017
In the citing paper
“P7-C1 microglia exhibited characteristic expression of many genes that have recently been shown to be up-regulated in degenerative disease-associated microglia (DAM)”
From Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing (2019) · cites this paper as Krasemann et al., 2017
In the citing paper
“We discovered a proliferative region-associated microglia (PAM) subset, mainly found in developing white matter, that share a characteristic gene signature with degenerative disease-associated microglia (DAM).”
From Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing (2019) · cites this paper as Krasemann et al., 2017
In the citing paper
“unlike DAM (Keren-Shaul et al., 2017; Krasemann et al., 2017), appearance of PAM did not depend on a TREM2-APOE axis”
From Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing (2019) · cites this paper as Krasemann et al., 2017
In the citing paper
“Particularly, we identified a subset of microglia, named proliferative region-associated microglia (PAM), that mimicked gene expression pattern of degenerative disease-associated microglia (DAM) (Keren-Shaul et al., 2017; Krasemann et al., 2017).”
From Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing (2019) · cites this paper as Krasemann et al., 2017
In the citing paper
“It has been shown that transcriptional changes in degenerative disease-associated microglia depend on the TREM2-APOE pathway, and the DAM signature genes such as Spp1, Gpnmb and Clec7a are suppressed in disease models that also lack Trem2 or Apoe (Keren-Shaul et al., 2017; Krasemann et al., 2017).”
From Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing (2019) · cites this paper as Krasemann et al., 2017
In the citing paper
“Indeed, while early postnatal PAM engulf newly formed oligodendrocytes and possibly newborn astrocytes during development, DAM are also phagocytic and involved in phagocytosis of Aβ plaques in AD models (Keren-Shaul et al., 2017; Krasemann et al., 2017).”
From Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing (2019) · cites this paper as Krasemann et al., 2017
In the citing paper
“DAM or MGnD are found in neurodegenerative disorders including AD, amyotrophic lateral sclerosis (ALS) and multiple sclerosis [41, 45].”
From Transcriptional and Epigenetic Regulation of Microglia in Health and Disease (2019) · cites this paper as [45]
In the citing paper
“Customized NanoString-based gene expression analysis, which uses molecular barcodes and microscopic imaging to detect and count unique transcripts in hybridization reactions, revealed APOE and TGFβ as the major upstream regulators of MGnD microglia.”
From Transcriptional and Epigenetic Regulation of Microglia in Health and Disease (2019) · cites this paper as [45]
In the citing paper
“Upregulation of APOE suppresses gene expression of microglial homeostatic transcriptional factors including Spi1, Mef2a, Mafb, Smad3”
From Transcriptional and Epigenetic Regulation of Microglia in Health and Disease (2019) · cites this paper as [45]
In the citing paper
“and induces inflammatory response via induction of transcription factors Bhlhe40, Tfec, Atf, and inflammatory miRNA miR-155”
From Transcriptional and Epigenetic Regulation of Microglia in Health and Disease (2019) · cites this paper as [45]
In the citing paper
“Krasemann et al. found dystrophic neurites stimulate TREM2 –APOE pathway that results in phenotypic switch from homeostatic to MGnD microglia [45].”
From Transcriptional and Epigenetic Regulation of Microglia in Health and Disease (2019) · cites this paper as [45]
In the citing paper
“In diseased states, microglia can become dysfunctional and neurotoxic, which are referred as disease-associated microglia (DAM) or microglia neurodegenerative phenotypes (MGnD).”
From Transcriptional and Epigenetic Regulation of Microglia in Health and Disease (2019) · cites this paper as [45]
In the citing paper
“which if genetically ablated, can reverse abnormal microglia signature and ameliorate disease in SOD1 mice, a mouse model for ALS [12, 45].”
From Transcriptional and Epigenetic Regulation of Microglia in Health and Disease (2019) · cites this paper as [45]
In the citing paper
“cbMg in the adult mouse brain show a primed/phagocytic microglia phenotype11–13 characterized by a less ramified morphology, reduced branching sites (Supplementary Fig. 1a), decreased cell volume (Supplementary Fig. 1b,c), and an increase in CD68+ lysosome content (Fig. 1a, Supplementary Fig. 1b,c).”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“Furthermore, cbMg show an increase in the expression of genes characteristic of immature microglia9,10, as well as genes that are expressed in neurodegenerative disease-associated microglia (such as primed microglia, MGnD, and DAMs)11–13 (Supplementary Fig. 5c,d, Supplementary Table 4).”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“The cerebellar microglia phenotype is reminiscent of microglia during early brain development9,10 as well as microglia associated with neurodegenerative disease11–13.”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“The increase in clearance-associated genes and the reduction in surveillance-related genes in PRC2-deficient stMg are reminiscent of transcriptional changes observed in microglia during neurodegenerative disease11–13 (Supplementary Fig. 11h).”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“This is another key characteristic feature of early microglia progenitors9,10 as well as microglia exposed to dying neurons during different diseases11–13.”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“We found that the cbMg-specific clearance gene expression pattern significantly overlaps with the signature of microglia associated with neurodegeneration11–13 and early brain development9,10, two stages of life characterized by enhanced neuronal attrition and heightened microglia clearance activity.”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“In particular, a significant fraction of the cbMg-expressed genes have been implicated in the detection, engulfment, and catabolism of debris both in peripheral macrophages carrying out cell clearance21 as well as in microglia associated with ageing and neurodegeneration11–13.”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“While PRC2-deficient stMg and cxMg show no up-regulation of complement or pro-inflammatory genes generally associated with microglia activation during neurodegeneration11–13,34, it is still plausible that their aberrant clearance activity may lead to the enhanced engulfment of C1q/C3-tagged spines, the presence of which increases with age44.”
From Epigenetic regulation of brain region-specific microglia clearance activity (2018) · cites this paper as [13]
In the citing paper
“The end-stage activated microglia appear to display a conserved core-expression profile harbouring certain degrees of diversity across individual disease phenotypes27,28.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“This signature is characterized by a suppression of microglial homeostatic genes, and an induction of pro-inflammatory genes as well as genes involved in microglial phagocytotic function targeting degenerated/injured neurons and amyloid plaques27,28.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“the expression of Apoe — the hallmark gene of the MGnD phenotype that has been found to be upregulated in microglia in all currently-assessed neurodegenerative diseases — is suppressed in M1 microglia.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“The MGnD phenotype can largely be recapitulated by injecting apoptotic neurons into mouse brain parenchyma, where the subset of microglia that are activated to phagocytose apoptotic neurons show a similar molecular phenotype to the MGnD phenotype28.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“TREM2−/− amyloid-β depositing mice consistently show downregulation of inflammatory genes, such as Tnf and Il1b45–47, and also of key genes associated with the MGnD phenotype, such as c-type lectin domain family 7 member A (Clec7a) and integrin subunit alpha X (Itgax)27,28”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“Interestingly, TREM2 shares the same pathways with ApoE in regulating the microglial neurodegenerative phenotype.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“TREM2 deletion in APPPS1–21 [G] or superoxide dismutase 1 (SOD1) mice [G] results in ApoE downregulation and a similar suppression of core inflammatory MGnD genes and restoration of homeostatic genes28.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“Targeting TREM2 signaling in the facial nerve axotomy model ameliorates neuronal loss28, and ablation of TREM2 in tauopathy mice attenuates neuroinflammation and neurodegeneration67, similar to the effect of ApoE deletion.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“ApoE deletion prevents full acquisition of the microglial neurodegenerative phenotype with suppression of key MGnD genes28”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“Contrary to LPS treatment where ApoE deletion amplifies the immune response, under neurodegenerative or neuroinflammatory conditions, ApoE deficiency attenuates inflammation28,69,97,107 and disease severity69,106,107.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [28]
In the citing paper
“emerging evidence suggests that APOE, a potent immune modulator and strongest of genetic risk factors for LOAD [113–115], may regulate neurodegeneration in a TREM2-mediated fashion [116, 117].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [117]
In the citing paper
“Itgax/CD11C is an integrin or cell surface antigen, and is up-regulated in a number of recent RNA-seq studies in response to amyloid plaques (58,59,61,84).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [84]
In the citing paper
“Recent important studies have also shown that impaired/absent Trem2 function attenuates the microglial response to amyloid pathology by regulating microglial number around plaques, regulating microglial activity, and restricting neuritic damage (37,61,84–87,95–99).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [84]
In the citing paper
“Indeed, a series of recent studies identified transcriptional signatures in response to AD-associated pathology, neurodegeneration and apoptotic neurons, which were in part dependent on Trem2 and included Igf1, Csf1, Itgax, Clec7a and Arg1, at least in mice (58,59,61,84,86).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [84]
In the citing paper
“Interestingly, when we tested expression of genes that show substantial changes in transgenic mice associated with AD (43,44) a number of aspects of gene expression were mimicked by anti-inflammatory IL-4 stimulation, particularly the increased expression of genes associated with the neurodegenerative signature, including Igf1, Itgax, Clec7a and Arg1 (58,59,61,84,86).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [84]
In the citing paper
“The downregulation of genes associated with microglial homeostasis, Tmem119, P2ry12, and Cx3cr1, have been identified in many murine models representing AD [44,77–80], amyotrophic lateral sclerosis (ALS) [44,77,79], and multiple sclerosis [79]; suggesting similar signaling pathways are present.”
From Untangling senescent and damage‐associated microglia in the aging and diseased brain (2023) · cites this paper as [79]
In the citing paper
“Intriguingly, P2ry13 and Gpr34, mouse orthologs of genes we identified in our human microglial gene set, are known to show down-regulation in so-called DAM (86–88) that are found in AD and other neurological disorders.”
From The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease (2019) · cites this paper as [88]
In the citing paper
“Another critical issue for future work will be to determine the mechanisms responsible for sexually dimorphic microglial gene expression profiles reported in mice (28, 88) and to what extent they apply to human microglia.”
From The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease (2019) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Polazzi, E., Mengoni, I., Caprini, M., Peña‐Altamira, E., Kurtys, E., & Monti, B. (2012) · Neurosignals · doi:10.1159/000337115 · Cited by 9,023
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Koopman, G., Reutelingsperger, C. P. M., Kuijten, G., Keehnen, R. M. J., Pals, S. T., & van Oers, M. H. J. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,687
Programmed Cell Death in Animal Development
Jacobson, M. D., Weil, M., & RAFF, M. C. (1997) · Cell · doi:10.1016/s0092-8674(00)81873-5 · Cited by 2,685
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543
Self-citationSmart-seq2 for sensitive full-length transcriptome profiling in single cells
Picelli, S., Björklund, Å. K., Faridani, O. R., Sagasser, S., Winberg, G., & Sandberg, R. (2013) · Nature Methods · doi:10.1038/nmeth.2639 · Cited by 2,358
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
Lavin, Y., Winter, D., Blecher-Gonen, R., David, E., Keren-Shaul, H., Merad, M., Jung, S., & Amit, I. (2014) · Cell · doi:10.1016/j.cell.2014.11.018 · Cited by 2,167
Koopman, G., Reutelingsperger, C., Kuijten, G., et al. (1994) · Blood · doi:10.1182/blood.v84.5.1415.bloodjournal8451415 · Cited by 2,068
the Immunological Genome Consortium, Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2419 · Cited by 1,972 · cited 3×
“We termed this microglial neurodegenerative phenotype MGnD, in contrast toM0-homeostatic adult microglia phenotype (Butovsky et al., 2014; Gautier et al., 2012; Hickman et al., 2013).”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
Self-citationOnset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
The microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511
Gosselin, D., Link, V. M., Romanoski, C. E., Fonseca, G. J., Eichenfield, D. Z., Spann, N. J., Stender, J. D., Chun, H. B., Garner, H., Geissmann, F., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.023 · Cited by 1,307
Microglia development follows a stepwise program to regulate brain homeostasis
Matcovitch-Natan, O., Winter, D. R., Giladi, A., Vargas Aguilar, S., Spinrad, A., Sarrazin, S., Ben-Yehuda, H., David, E., Zelada González, F., Perrin, P., et al. (2016) · Science · doi:10.1126/science.aad8670 · Cited by 1,180 · cited 8×
“1 to establish microgliaspecific enhancer profiles, including TGFb signaling (Butovsky et al., 2014; Gosselin et al., 2014; Matcovitch-Natan et al., 2016).”
BackgroundInfluentialMicroglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
Self-citationTREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840
Self-citationYuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
Streit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727
Cutting Edge: TREM-2 Attenuates Macrophage Activation
Turnbull, I. R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3520 · Cited by 688
Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 3×
“Consistent with previous findings (Jay et al., 2015), the Ab-plaque load was decreased in APP-PS1:Trem2 / mice (Figure 5H).”
BackgroundResultSelf-citationChiu, I. M., Morimoto, E. T. A., Goodarzi, H., Liao, J. T., O’Keeffe, S., Phatnani, H. P., Muratet, M., Carroll, M. C., Levy, S., Tavazoie, S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.06.018 · Cited by 651
The kainic acid model of temporal lobe epilepsy
Lévesque, M., & Avoli, M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.011 · Cited by 650
Holtman, I. R., Raj, D. D., Miller, J. A., Schaafsma, W., Yin, Z., Brouwer, N., Wes, P. D., Möller, T., Orre, M., Kamphuis, W., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0203-5 · Cited by 619
A new fate mapping system reveals context-dependent random or clonal expansion of microglia
Tay, T. L., Mai, D., Dautzenberg, J., Fernández-Klett, F., Lin, G., Sagar, Datta, M., Drougard, A., Stempfl, T., Ardura-Fabregat, A., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4547 · Cited by 597
Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587
Sall1 is a transcriptional regulator defining microglia identity and function
Buttgereit, A., Lelios, I., Yu, X., Vrohlings, M., Krakoski, N. R., Gautier, E. L., Nishinakamura, R., Becher, B., & Greter, M. (2016) · Nature Immunology · doi:10.1038/ni.3585 · Cited by 570
ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion
Huang, Y.-W. A., Zhou, B., Wernig, M., & Südhof, T. C. (2017) · Cell · doi:10.1016/j.cell.2016.12.044 · Cited by 528
Activation of Necroptosis in Multiple Sclerosis
Ofengeim, D., Ito, Y., Najafov, A., Zhang, Y., Shan, B., DeWitt, J. P., Ye, J., Zhang, X., Chang, A., Vakifahmetoglu-Norberg, H., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.051 · Cited by 526
Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., & Huang, Y. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5476-05.2006 · Cited by 524
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481
Self-citationBcl-2: Prolonging Life in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis
Kostić, V., Jackson-Lewis, V. R., de Bilbao, F., Dubois‐Dauphin, M., & Przedborski, S. (1997) · Science · doi:10.1126/science.277.5325.559 · Cited by 477
Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease
Jay, T. R., Hirsch, A. M., Broihier, M. L., Miller, C. M., Neilson, L. E., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2110-16.2016 · Cited by 457
TMEM119 marks a subset of microglia in the human brain
Satoh, J., Kino, Y., Asahina, N., Takitani, M., Miyoshi, J., Ishida, T., & Saito, Y. (2016) · Neuropathology · doi:10.1111/neup.12235 · Cited by 434
Stadelmann, C., Deckwerth, T. L., Srinivasan, A. N., Bancher, C., Brück, W., Jellinger, K. A., & Lassmann, H. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65460-0 · Cited by 432
Self-citationAlzheimer's disease. A double-labeling immunohistochemical study of senile plaques.
Dickson, D. W., Farlo, J., Davies, P., Crystal, H., Fuld, P. A., & Yen, S. H. (1988) · PubMed Central · Cited by 383
Targeting mi R‐155 restores abnormal microglia and attenuates disease in SOD 1 mice
Butovsky, O., Jedrychowski, M. P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D. J., Wu, P. M., Doykan, C. E., Kiner, O., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24304 · Cited by 358
Self-citationTREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury
Mazaheri, F., Snaidero, N., Kleinberger, G., Madore, C., Daria, A., Werner, G., Krasemann, S., Capell, A., Trümbach, D., Wurst, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201743922 · Cited by 351
Self-citationEvidence for Synaptic Apoptosis
Mattson, M. P., Keller, J. N., & Begley, J. G. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6863 · Cited by 341
Aberrant neurofilament phosphorylation in Alzheimer disease.
Sternberger, N. H., Sternberger, L. A., & ULRICH, J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4274 · Cited by 338
Self-citationOrre, M., Kamphuis, W., Osborn, L. M., Melief, J., Kooijman, L., Huitinga, I., Klooster, J., Bossers, K., & Hol, E. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.008 · Cited by 279
Suárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272
Self-citationYuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.016 · Cited by 219
CD33 modulates TREM2: convergence of Alzheimer loci
Chan, G., White, C. C., Winn, P. A., Cimpean, M., Replogle, J. M., Glick, L. R., Cuerdon, N. E., Ryan, K. J., Johnson, K. A., Schneider, J. A., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4126 · Cited by 162
Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
Kim, J., Eltorai, A. E. M., Jiang, H., Liao, F., Verghese, P. B., Kim, J., Stewart, F. R., Basak, J. M., & Holtzman, D. M. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121274 · Cited by 160 · cited 1×
“APOE both accumulates in amyloid plaques and facilitates Ab aggregation (Kim et al., 2012).”
BackgroundSelf-citationCaspase Dependent DNA Fragmentation Might Be Associated with Excitotoxicity in Alzheimer Disease
Masliah, E., Mallory, M. E., Alford, M. F., Tanaka, S., & Hansen, L. A. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199811000-00007 · Cited by 151
Grutzendler, J., Helmin, K. A., Tsai, J., & Gan, W. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.003 · Cited by 143
The miR-155–PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation
Lu, D., Nakagawa, R., Lazzaro, S., Staudacher, P., Abreu‐Goodger, C., Henley, T., Boiani, S., Leyland, R., Galloway, A., Andrews, S., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140338 · Cited by 106
miR-155 Inhibits Expression of the MEF2A Protein to Repress Skeletal Muscle Differentiation
Seok, H., Tatsuguchi, M., Callis, T. E., He, A., Pu, W. T., & Wang, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273276 · Cited by 98
CSF Apo-E levels associate with cognitive decline and MRI changes
Initiative, F. T. A. D. N., Toledo, J. B., Da, X., Weiner, M. W., Wolk, D. A., Xie, S. X., Arnold, S. E., Davatzikos, C., Shaw, L. M., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1236-0 · Cited by 71
Verheijden, S., Bottelbergs, A., Krysko, O., Krysko, D. V., Beckers, L., De Munter, S., Van Veldhoven, P. P., Wyns, S., Kulik, W., Nave, K.-A., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.006 · Cited by 54
Self-citationApolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis
Shin, S., Walz, K. A., Archambault, A. S., Sim, J., Bollman, B. P., Koenigsknecht-Talboo, J., Cross, A. H., Holtzman, D. M., & Wu, G. F. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.03.010 · Cited by 32
Self-citationLarner, A. J. (1995) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106950 · Cited by 23
Microglia and Microglia-Like Cell Differentiated from DC Inhibit CD4 T Cell Proliferation
Bai, B., Song, W., Ji, Y., Liu, X., Tian, L., Wang, C., Chen, D., Zhang, X., & Zhang, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007869 · Cited by 22
Wagner, T., Bartelt, A., Schlein, C., & Heeren, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145102 · Cited by 21
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Self-citationNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Microglia states and nomenclature: A field at its crossroads
Paolicelli, R. C., Sierra, A., Stevens, B., Tremblay, M.-E., Aguzzi, A., Ajami, B., Amit, I., Audinat, E., Bechmann, I., Bennett, M., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.020 · Cited by 1,973
Self-citation
Metadata
- Authors
- Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., Greco, D. J., Smith, S. T., Tweet, G., Humulock, Z., Zrzavy, T., Conde-Sanroman, P., Gacias, M., Weng, Z., Chen, H., Tjon, E., Mazaheri, F., Hartmann, K., Madi, A., Ulrich, J. D., Glatzel, M., Worthmann, A., Heeren, J., Budnik, B., Lemere, C., Ikezu, T., Heppner, F. L., Litvak, V., Holtzman, D. M., Lassmann, H., Weiner, H. L., Ochando, J., Haass, C., & Butovsky, O.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Massachusetts Chan Medical School (US)
- Medical University of Vienna (AT)
- Icahn School of Medicine at Mount Sinai (US)
- German Center for Neurodegenerative Diseases (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Washington University in St. Louis (US)
- Harvard University (US)
- Boston University (US)
- NeuroCure Cluster of Excellence (DE)
- Corresponding author
- Butovsky, Oleg
- ORCID
- Krasemann, Susanne
- Madore, Charlotte
- Cialic, Ron
- Calcagno, Narghes
- Beckers, Lien
- Xu, Yang
- Tweet, George
- Zrzavy, Tobias
- Gacias, Mar
- Weng, Zhiping
- Mazaheri, Fargol
- Madi, Asaf
- Ulrich, Jason D.
- Glatzel, Markus
- Worthmann, Anna
- Budnik, Bogdan
- Lemere, Cynthia
- Ikezu, Tsuneya
- Heppner, Frank L.
- Holtzman, David M.
- Lassmann, Hans
- Weiner, Howard L.
- Ochando, Jordi
- Haass, Christian
- Butovsky, Oleg
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 47
- Issue
- 3
- Pages
- 566-581.e9
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC5719893
- OpenAlex
- W2754890392
- Cited by
- 2,979
- References
- 61
- Citations by year
- 2026: 429 · 2025: 418 · 2024: 377 · 2023: 344 · 2022: 395 · 2021: 339 · 2020: 310 · 2019: 202 · 2018: 149 · 2017: 13
- FWCI
- 92.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 383 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lirias (submittedVersion, other-oa)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- HAL (submittedVersion)
- DZNE Pub (submittedVersion)
- Funders
- NIH National Institute of Neurological Disorders and Stroke (1R01NS088137)
- NIH National Institute on Aging (R01AG051812, R01AG054672)
- National Multiple Sclerosis Society (5092A1)
- Amyotrophic Lateral Sclerosis Association (2087)
- Nancy Davis Foundation Faculty Award
- Cure Alzheimer’s Fund (2017APOE)
- Department of Defense (AL120029)
- Thome Foundation (2011D002865)
- NIH-NIA (R01AG043975, R01AG040092, RF1AG054199-01)
- European Research Council (321366-Amyloid)
- Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy)
- Cure Alzheimer's Fund
- MetLife Foundation Award
- DFG (SFB841, P50AG05681, P01-AG0399, GRK1459, SFB877)
- Austrian Science Foundation Project (P27744-B27)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- TREM2, apolipoprotein E, microglia, neurodegenerative diseases, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, amyloid plaques, microglial phenotype, homeostatic microglia, therapeutic target
- MeSH terms
- Superoxide Dismutase-1, Alzheimer Disease, Animals, Apolipoproteins E, Cerebral Cortex, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Female, Gene Expression Regulation, Humans, Immune Tolerance, Membrane Glycoproteins, Mice, Transgenic, Monocytes, Neurons, Phagocytosis, Phenotype, Receptors, Immunologic, Signal Transduction, Cluster Analysis, Transforming Growth Factor beta, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Apoptosis, Microglia, Mice, Knockout, Gene Targeting, Neurodegenerative Diseases, Gene Expression Profiling, Mice, Plaque, Amyloid, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
